What is the 13F Pro Quality Score for ABBV?

13F Pro ranks AbbVie Inc. (ABBV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABBV's current score at https://13fpro.ai/company/ABBV (free sign-up required for the full ranking).

Which hedge funds own the most ABBV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABBV include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ABBV as soon as new 13F filings post.

Where does 13F Pro source ABBV data?

All AbbVie Inc. fundamentals and ownership data come directly from SEC EDGAR. AbbVie Inc. files with the SEC under CIK 1551152. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABBV in?

AbbVie Inc. (ABBV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ABBV's revenue?

Per AbbVie Inc.'s latest 10-Q filed with the SEC on 2026-08-03, the biggest revenue drivers are: Skyrizi ($5,505M, +24.4% YoY); Rinvoq ($2,525M, +24.5% YoY); Vraylar ($1,071M, +18.9% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ABBV.

What are ABBV's largest expenses?

AbbVie Inc.'s latest 10-Q reports these as the largest expense items: Cost of products sold ($4,291M); Selling, general and administrative ($3,632M, +12% YoY); Research and development ($2,344M, +10% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ABBV research updated on 13F Pro?

ABBV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AbbVie Inc.(ABBV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmega

Institutional-grade research for retail investors

SEC EDGAR: CIK 1551152 ABBV stock profile & AI dashboard →

13F Pro Quality Score

72.6/100

Rank #148 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

54.1/100

Profitability

70.1/100

Balance Sheet

68.1/100

Earnings Quality

90.4/100

Free Cash Flow

82.1/100

Institutional Flow

67.2/100

Revenue Scale

97.6/100

Dilution Risk

45.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ABBV Scores 73/100

exact factor attribution · 2026-09-11

ABBV's composite is driven by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.1 pts

98th pct

Free cash flow

+4.8 pts

82th pct

Earnings quality

+4.0 pts

90th pct

Profitability

+3.0 pts

70th pct

Capital efficiency

+1.8 pts

68th pct

Institutional flow

+0.9 pts

67th pct

Revenue growth

+0.8 pts

54th pct

Earnings growth

+0.4 pts

58th pct

Shareholder dilution

-0.2 pts

45th pct

Latest change (2026-08-03): 59 → 60 · ↑ Profit margin 39→52; despite ↓ Revenue growth 56→48

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ABBV Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for AbbVie Inc. (ABBV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABBV at 72.6/100 on a 32-signal composite quality model, placing it at rank #148 of 2,961 stocks — the top 5% of the AI-ranked universe. ABBV scores in the top quartile across revenue scale (97.6), earnings quality (90.4), free cash flow (82.1). Shareholder dilution risk is elevated at 45.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbbVie Inc. reports quarterly revenue of $17.0B, net income of $3.6B, free cash flow of $3.1B. Top institutional holders of ABBV by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABBV trades on the NYSE exchange and files with the SEC under CIK 1551152. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABBV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbbVie Inc. directly from SEC EDGAR. AbbVie Inc.'s 13F Pro composite quality score has ranged between 58 and 82 since 2021, currently 72.6 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about AbbVie Inc.

Quirks, history, and lore behind ABBV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · large-cap · listed on the NYSE · headquartered in Illinois.
2
The Numbers
Annual revenue around $55 billion, built heavily on a single blockbuster drug that for years was the world's best-selling medicine by revenue.
3
The History
Spun off from a major pharmaceutical parent in 2013, it was handed the crown jewel drug and told to go make its own fortune — which it very much did.
4
The Secret
Its R&D pipeline leans hard into immunology, oncology, and neuroscience, and it has spent aggressively on acquisitions to reduce its dependence on that one famous drug.
5
The Lore
When its flagship drug's patents began expiring, the company fought biosimilar rivals with a patent thicket so vast it became a case study in pharmaceutical legal strategy — and a congressional punching bag.
6
The Giveaway
If your joints ache, you've probably seen the ads: Humira, the rheumatoid-arthritis injection that single-handedly redefined what a blockbuster drug could earn.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ABBV's Business? Latest 10-Q Breakdown

✓ 39/39 datapoints verified

AI-extracted from AbbVie Inc.'s 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenues rose 10.2% to $17.0B as Skyrizi ($5,505M, +24.4%) and Rinvoq ($2,525M, +24.5%) more than offset Humira's 35.9% decline; net earnings reached $3,616M.

Biggest Revenue Drivers

Skyrizi$5,505M+24.4% YoY

Continued strong market share uptake as well as market growth across all indications

Rinvoq$2,525M+24.5% YoY

Continued strong market share uptake as well as market growth across all indications

Biggest Revenue Drivers

Total revenue: $17.0B+10.2% YoY

Skyrizi$5,505M+24.4% YoY

Continued strong market share uptake as well as market growth across all indications

Rinvoq$2,525M+24.5% YoY

Continued strong market share uptake as well as market growth across all indications

Vraylar$1,071M+18.9% YoY

Continued market share uptake and market growth as well as favorable pricing

Botox Therapeutic$1,042M+12.2% YoY

Market growth as well as continued market share uptake

Humira$756M-35.9% YoY

Continued impact of direct biosimilar competition following the loss of exclusivity

Largest Expense Items

Cost of products sold$4,291M

Includes $1.7 billion of intangible asset amortization; decreased amortization lowered fixed costs

Selling, general and administrative$3,632M+12% YoY

Continued leverage from net revenues growth, offset by higher litigation reserve charges

Research and development$2,344M+10% YoY

Increased to support all stages of the company's pipeline assets

Acquired IPR&D and milestones$291M

Down from $823M; prior-year quarter included $350M Gubra and $335M ADARx upfront charges

Margins: Gross margin was 75% of net revenues versus 72% a year ago, increasing primarily due to higher net revenues against lower fixed costs driven by decreased amortization of intangible assets.

Watch Items from the Filing

Three U.S. wholesalers accounted for 82% of total net accounts receivable at June 30, 2026, and substantially all U.S. pharmaceutical product net revenues.
Contingent consideration liabilities reached $27,495M, with a $1.5 billion fair value charge in the quarter driving other expense, net of $1,475M.
Humira fell to $756M from $1,180M on biosimilar competition; U.S. Humira dropped 47.0% to $425M.
Proposed $10.9 billion Apogee acquisition, backed by a new $10.0 billion 364-day term loan facility, against total deficit of $(5,888)M.
Litigation accrual was $1.7 billion; approximately 1,300 Biocell ALCL suits sit in MDL 2921, and Botox was selected for Medicare government-set prices beginning 2028.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$17.0B

Net Income

Q2 2026

$3.6B

Free Cash Flow

Q2 2026

$3.1B

ROIC

Q2 2026

39.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.6% YoY

$61.16BFY 2025

FY22 $58.05BFY23 $54.32BFY24 $56.33BFY25 $61.16B

Net Income

-1.2% YoY

$4.23BFY 2025

FY22 $11.84BFY23 $4.86BFY24 $4.28BFY25 $4.23B

Operating Income

+65.0% YoY

$15.07BFY 2025

FY22 $18.12BFY23 $12.76BFY24 $9.14BFY25 $15.07B

EPS (Diluted)

-1.3% YoY

$2.36FY 2025

FY22 $6.63FY23 $2.72FY24 $2.39FY25 $2.36

Total Assets

-0.9% YoY

$133.96BFY 2025

FY22 $138.81BFY23 $134.71BFY24 $135.16BFY25 $133.96B

Total Debt

-0.8% YoY

$73.06BFY 2025

FY22 $67.26BFY23 $66.44BFY24 $73.64BFY25 $73.06B

Op. Cash Flow

+1.2% YoY

$19.03BFY 2025

FY22 $24.94BFY23 $22.84BFY24 $18.81BFY25 $19.03B

Free Cash Flow

-0.1% YoY

$17.82BFY 2025

FY22 $24.25BFY23 $22.06BFY24 $17.83BFY25 $17.82B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$61.16B +8.6%	$56.33B +3.7%	$54.32B -6.4%	$58.05B +3.3%	$56.20B +22.7%	$45.80B
Net Income	$4.23B -1.2%	$4.28B -12.0%	$4.86B -58.9%	$11.84B +2.5%	$11.54B +150.0%	$4.62B
Operating Income	$15.07B +65.0%	$9.14B -28.4%	$12.76B -29.6%	$18.12B +1.1%	$17.92B +57.7%	$11.36B
EPS (Diluted)	$2.36 -1.3%	$2.39 -12.1%	$2.72 -59.0%	$6.63 +2.8%	$6.45 +137.1%	$2.72
Total Assets	$133.96B -0.9%	$135.16B +0.3%	$134.71B -2.9%	$138.81B -5.3%	$146.53B -2.7%	$150.56B
Total Debt	$73.06B -0.8%	$73.64B +10.9%	$66.44B -1.2%	$67.26B -24.0%	$88.46B -5.3%	$93.45B
Operating Cash Flow	$19.03B +1.2%	$18.81B -17.7%	$22.84B -8.4%	$24.94B +9.5%	$22.78B +29.5%	$17.59B
Free Cash Flow	$17.82B -0.1%	$17.83B -19.2%	$22.06B -9.0%	$24.25B +10.3%	$21.99B +31.0%	$16.79B

Get alerted when ABBV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AbbVie Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABBV

BlackRock, Inc.
$37.6B149,488,412 sh
VANGUARD CAPITAL MANAGEMENT LLC
$29.0B115,396,098 sh
STATE STREET CORP
$20.8B82,596,748 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$12.2B48,477,996 sh
JPMORGAN CHASE & CO
$12.2B47,862,796 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.8B46,998,433 sh
MORGAN STANLEY
$9.8B38,901,001 sh
Capital Research Global Investors
$7.6B30,101,551 sh
NORGES BANK
$6.4B25,554,538 sh
BANK OF AMERICA CORP /DE/
$5.3B21,237,764 sh

Fund	Value	Shares
BlackRock, Inc.	$37.6B	149,488,412
VANGUARD CAPITAL MANAGEMENT LLC	$29.0B	115,396,098
STATE STREET CORP	$20.8B	82,596,748
VANGUARD PORTFOLIO MANAGEMENT LLC	$12.2B	48,477,996
JPMORGAN CHASE & CO	$12.2B	47,862,796
GEODE CAPITAL MANAGEMENT, LLC	$11.8B	46,998,433
MORGAN STANLEY	$9.8B	38,901,001
Capital Research Global Investors	$7.6B	30,101,551
NORGES BANK	$6.4B	25,554,538
BANK OF AMERICA CORP /DE/	$5.3B	21,237,764

Companies Similar to ABBV

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

JNJ

JOHNSON & JOHNSON

AI score

Highly similar · 55 shared holders

Capital World Investors Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

ABT

ABBOTT LABORATORIES

AI score

Highly similar · 49 shared holders

Capital Research Global Investors Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

AMGN

AMGEN INC

AI score

Highly similar · 45 shared holders

Capital World Investors Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

MRK

Merck & Co., Inc.

AI score

Highly similar · 50 shared holders

Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

LLY

ELI LILLY & Co

AI score

Highly similar · 56 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

SYK

STRYKER CORP

AI score

Very similar · 38 shared holders

Capital Research Global Investors Boston Partners NORDEA INVESTMENT MANAGEMENT AB

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 45 shared holders

NORDEA INVESTMENT MANAGEMENT AB Robeco Institutional Asset Management B.V.Capital International Investors

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 42 shared holders

Capital World Investors Capital Research Global Investors Capital International Investors

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

ABT

ABBOTT LABORATORIES

Put ABBV on your watchlist

Track score changes the day AbbVie Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABBV a good stock to buy?

13F Pro's AI-powered analysis of AbbVie Inc. (ABBV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABBV are available on the ABBV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABBV is classified as a mega company.

Which hedge funds own ABBV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABBV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AbbVie Inc.'s investment landscape.